Outsourced Pharma Editorial

  1. NK Cell Therapies: How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach 4/24/2024

    We caught up with Chris Horan, Artiva Biotherapeutics' CTO, to discuss natural killer cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.

  2. Improving Governance And Compliance With Knowledge Management 4/23/2024

    Knowledge management — it’s not just a soulless exercise. In the last part of his series, Hirsh helps bridge the gap between compliance and business needs.

  3. China’s Rising Role On The Global Stage In The Oncology Market 4/23/2024

    The oncology pharma market has largely been dominated by European and U.S. companies. With the ongoing expansion of the Chinese biopharma sector, innovative oncology drugs will emerge from China and compete on the international market.

  4. Nothing To See Here! Just Big Pharma Investments In China 4/22/2024

    WuXi AppTec assists U.S.-based biotechs to develop and supply drugs to U.S. patients. Western-based Pharma assists the development of China's industry, the China Communist Party (CCP) by extension, and patients there. Guess which is under assault? Chief Editor Louis Garguilo tries to figure it all out.

  5. GMP Plant Uniform Lockers And Procedures: Best Practices 4/22/2024

    As the use of GMP plant uniforms has gained acceptance, locker room layouts have arisen across companies and sites. This article examines alternatives and optimized approaches.

  6. A Deeper Look At What's Driving Dependence On Biotech Contract Manufacturers 4/19/2024

    Are you struggling to find CDMO capacity? Here are some of the drivers behind the contract manufacturing market's exponential growth.

  7. Developing A Process Performance Qualification Master Plan For Gene Therapies 4/19/2024

    This article provides considerations and a framework for a Process Performance Qualification Master Plan in the gene therapy industry. It is useful for sponsors with any level of experience.

  8. CDMOs Pelted By Slings And Arrows 4/18/2024

    Chief Editor Louis Garguilo thought he was precipitating a frontal assault by canvassing the Outsourced Pharma Editorial Advisory Board with questions such as: When outsourcing development and manufacturing, what are the challenges, and where are your pain points? But before anyone claims “one-sided,” please read on.

  9. The EU’s Ban On TiO2 In Food May Impact Pharma. Here’s What You Should Know. 4/18/2024

    Titanium dioxide (TiO2) is used as a food additive and OSD pharmaceutical excipient. In 2020, the European Food Safety Authority noted data gaps regarding particle size, which can affect its toxicological properties, so the European Commission banned it as a food additive. Here's how this could impact pharma.

  10. What Time Is Best To Bring My CDMO On Board? 4/17/2024

    The answer might be sooner than you think and entail more transparency than you're used to.